Mar 1, 2019 5:41pm EST Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder
Jan 2, 2019 7:00am EST Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion
Dec 18, 2018 7:00am EST Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
Nov 29, 2018 7:00am EST Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes
